A new class of highly popular diabetes drugs have changed the landscape for conventional wisdom on obesity and weight loss, but cost of the drug and weight stigma are preventing the drug from widespread authorization by insurers, including Medicare.
Ozempic and its sister drug Wegovy, produced by NovoNordisk, were the first of two...